Dashboard
Manage Tickers

GSKGSK plc

NYSE gsk.com


$ 43.68 $ 0.54 (1.25 %)    

Friday, 06-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 43.67
$ 43.67 x 200
$ 43.68 x 200
-- - --
$ 32.11 - $ 45.37
3,763,259
na
94.16B
$ 0.52
$ 14.99
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-battles-backlog-of-drug-factory-inspections-since-covid-19
FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

gsks-asthma-drug-meets-main-goal-in-phase-3-study-in-patients-with-smokers-lungs-prepares-competition-with-amgenastrazenecas-drug
GSK's Asthma Drug Meets Main Goal In Phase...
09/06/2024 10:56:44

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

gsks-matinee-phase-3-trial-of-nucala-mepolizumab-met-the-primary-endpoint-showing-a-statistically-significant-and-clinically-meaningful-reduction-in-the-annualized-rate-of-moderatesevere-exacerbations-versus-placebo-in-chronic-obstructive-pulmonary-disease
GSK's MATINEE Phase 3 Trial Of Nucala (Mep...
09/06/2024 09:31:13

gsk-statement-on-zantac-ranitidine-litigation-delaware-supreme-court-to-review-superior-courts-daubert-decision
GSK Statement On Zantac (Ranitidine) Litig...
08/27/2024 18:23:31

- Reuters 

correction-gsk-fda-breakthrough-therapy-news-was-reported-on-august-20
CORRECTION: GSK FDA Breakthrough Therapy N...
08/27/2024 18:12:56

novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets
Novo Nordisk's Ozempic Might Be Among 2027...
08/23/2024 18:21:18

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...

the-fda-has-granted-breakthrough-therapy-designation-to-gsks-gsk5764227-an-investigational-b7-h3-targeted-antibody-drug-conjugate-being-evaluated-for-extensive-stage-small-cell-lung-cancer-with-disease-progression-on-or-after-platinum-based-chemotherapy-relapsed-or-refractory
The FDA Has Granted Breakthrough Therapy D...
08/20/2024 10:34:18

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
08/19/2024 17:35:23

florida-ruling-upholds-gsks-stance-on-once-popular-heart-burn-drug-zantac-not-being-associated-with-cancer-risk
Florida Ruling Upholds GSK's Stance On Onc...
08/16/2024 13:00:55

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a bro...

florida-state-courts-ruling-finds-in-favor-of-gsk-and-other-defendants-excluding-plaintiffs-experts-general-and-specific-causation-testimony-that-ranitidine-was-a-significant-risk-factor-for-wilsons-prostate-cancer
Florida State Court's Ruling Finds In Favo...
08/16/2024 10:25:13

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/15/2024 17:35:23

new-european-regulations-could-hinder-rare-disease-treatments-pharma-industry-raises-concerns-over-stricter-clinical-trial-rules
New European Regulations Could Hinder Rare...
08/13/2024 17:58:57

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...

wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts Spotl...
08/12/2024 13:00:09

moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-competitive-pressure-from-gsk-pfizer
Moderna Stock Trading Lower On Dismal Guid...
08/02/2024 18:22:50

Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...

gsks-dostarlimab-gxly-fda-indication-expanded-for-endometrial-cancer-with-chemotherapy
GSK's Dostarlimab-Gxly FDA Indication Expa...
08/01/2024 19:01:11

- Reuters 

tech-stocks-on-track-for-best-session-in-5-months-ahead-of-fed-meeting-small-caps-target-highest-close-since-january-2022-whats-driving-markets-wednesday
Tech Stocks On Track For Best Session In 5...
07/31/2024 17:23:22

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...

british-pharma-giant-gsks-blockbuster-shingles-and-respiratory-syncytial-virus-vaccine-q2-sales-miss-expectations-cuts-annual-vaccine-revenue-guidance
British Pharma Giant GSK's Blockbuster Shi...
07/31/2024 15:27:10

GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong...

wall-street-remains-on-track-for-amd-led-rebound-ahead-of-fed-decision-meta-earnings-analyst-says-the-bull-tends-to-remain-despite-near-term-volatility
Wall Street Remains On Track For AMD-Led R...
07/31/2024 11:55:46

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...

gsk-expects-2024-turnover-growth-of-7-9-previously-5-7-with-core-operating-profit-growth-of-11-13-previously-9-11-and-core-eps-growth-of-10-12-previously-8-10
GSK Expects 2024 Turnover Growth Of 7%-9% ...
07/31/2024 08:49:16

gsk-q2-2024-adj-eps-110-beats-099-estimate-sales-9947b-beat-9661b-estimate
GSK Q2 2024 Adj. EPS $1.10 Beats $0.99 Est...
07/31/2024 08:47:32

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION